LENSAR, Inc. (LNSR) Market Cap
LENSAR, Inc. has a market capitalization of $65.8M.
Financials based on reported quarter end 2025-12-31
Price: $5.44
▲ 0.09 (1.68%)
Market Cap: 65.80M
NASDAQ · time unavailable
CEO: Nicholas T. Curtis
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2020-10-02
Website: https://www.lensar.com
LENSAR, Inc. (LNSR) - Company Information
Market Cap: 65.80M · Sector: Healthcare
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Analyst Sentiment
Based on 3 ratings
Analyst 1Y Forecast: $10.00
Average target (based on 1 sources)
Consensus Price Target
Low
$10
Median
$10
High
$10
Average
$10
Potential Upside: 83.8%
Price & Moving Averages
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"LNSR reported revenue of ~$0.02B (=$16.03M) for the quarter ended 2025-12-31, with net income of -$1.46M and EPS of -$0.12. Net margin was approximately -9.1% (loss), indicating profitability pressure. Operating cash flow was $0.62M, with free cash flow (FCF) of $0.62M, and no dividends or capital expenditures were reported for the period. From a cash-flow perspective, the business generated positive operating cash despite the net loss, which may reflect working-capital dynamics; however, the absence of recorded capex and the lack of longer-term FCF history limit confidence in sustainability. Balance-sheet metrics show total liabilities of $83.67M versus total assets of $71.43M, resulting in negative equity of -$26.02M. Net debt is -$10.24M, suggesting more net cash than debt, but leverage remains a key concern given negative equity. Valuation data is constrained (no market cap and limited analyst range). With the stock at $5.96 and a 1-year change of -57.8%, shareholder returns have been strongly negative on capital appreciation, outweighing any positive period FCF. Overall, the main investor focus is likely on improving profitability and restoring balance-sheet equity while maintaining cash generation."
Revenue Growth
Only a single-quarter revenue figure ($16.03M) is provided, so growth rate vs. prior periods cannot be assessed. Revenue is positive, but profitability indicates execution pressure.
Profitability
Net income of -$1.46M and EPS of -$0.12 imply a net margin around -9.1%. Persistent losses reduce confidence in business efficiency and operating leverage.
Cash Flow Quality
Operating cash flow and free cash flow were both $0.62M, indicating cash generation despite the net loss. However, capex is shown as $0 and FCF stability over time is unknown.
Leverage & Balance Sheet
Negative equity of -$26.02M (liabilities of $83.67M vs. assets of $71.43M) is a material risk metric. Net debt is -$10.24M (net cash), which helps liquidity, but the equity position remains stressed.
Shareholder Returns
Total shareholder return has been weak: the stock declined -57.8% over 1 year (and -51.7% over 6 months). No dividends and no buybacks are provided, so capital appreciation has dominated returns negatively.
Analyst Sentiment & Valuation
A consensus price target of $10 (high=low=10) suggests some baseline upside expectation, but valuation multiples (P/E, FCF yield, ROE) and market cap are not provided. With large declines, valuation support may be uncertain.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
LENSAR exited Q4 2025 with an operational rebound setup after the Alcon merger was terminated due to FTC concerns. The company emphasized technology validation (ALLY as next-gen, machine-learning-based laser planning) and reported strong underlying install/procedure momentum despite transaction disruption. Q4 revenue was $16M (-4% YoY) driven by lower system sales, especially OUS (1 sale vs 10 a year prior). However, recurring revenue grew: Q4 recurring revenue was $12.7M and represented 79% of Q4 revenue; full-year recurring revenue reached $46.3M (+15%). Gross margin improved in Q4 (43% vs 42%, ~+100 bps) but declined for FY to 46% vs 48% (~-200 bps) due to inflation and tariffs. Management expects gradual normalization through 2026, with clearer OUS/Southeast Asia acceleration into 1H 2027 as distributors restart tenders and replace competitive systems. Key near-term risk remains distributor-driven OUS restart timing and tender cycle delays.
Growth Catalysts
- ALLY installed base expanded nearly 50% vs year-end 2024; total installed base ~200 ALLY systems by Q4 exit
- Procedure volume growth: Q4 procedures +~20% YoY; full year procedures +22% YoY to 206,000+ globally
- Replacement-driven market share gains: US procedure share from 14% to 23.4% by end of 2025 (+~9.5 market share points in ~3.5 years)
- High utilization and throughput: US ALLY systems perform ~27% more procedures than national average; expected to continue on average ~600 procedures/year per US ALLY unit (with ramp from new installs)
- Astigmatism management feature: over 65% of procedures involve astigmatism management; femto-naive surgeons were ~50% of Q4 new business and expected to continue
Business Development
- Alcon: joint acquisition announcement in March 2025; ALY recognized by Alcon publicly as part of the acquisition process
- Federal Trade Commission (FTC): FTC intent to enjoin the merger drove mutual termination decision
- International distributors re-engagement post-termination (no specific names provided)
- Germany: referenced large private equity group customer/distribution ecosystem (LENSAR described as a primary supplier there)
Financial Highlights
- Q4 total revenue: $16.0M, -4% YoY (primarily lower system sales)
- Q4 gross margin: 43% vs 42% prior year (+~100 bps)
- Full-year gross margin: 46% vs 48% prior year (-~200 bps)
- Gross margin headwind attributed to inflationary raw material/production costs plus tariffs assessed in 2025; company did not pass tariff costs to customers
- 2025 revenue growth: +9% YoY; recurring revenue +15% YoY (offsetting system sales decline)
- Q4 recurring revenue: $12.7M; annualized >$50M; recurring revenue represented 79% of Q4 revenue
- Exit recurring revenue run-rate: full year 2025 recurring revenue $46.3M (+15% vs $40.1M in 2024)
- Adjusted EBITDA: positive for the year; Q4 adjusted EBITDA $0.595M
- Expense pressure in Q4: merger-related costs ~ $3.5M; SG&A $10.3M (+51% YoY); total operating expenses $11.9M (+41% YoY)
Capital Funding
- Cash/timing from termination: $10M merger transaction deposit in escrow became available; cash reported at Dec 31: $18M (deposit liability eliminated in Q1 2026)
- Acquisition costs: $17.1M total acquisition costs in 2025; $14.0M unpaid as of Dec 31
- Unpaid acquisition costs unwind: ~$4.3M written off via adviser concession; remaining ~$5.0M payable starting May 2027 (payment deferral)
- Backlog: 13 ALLY systems pending installation at 2025 exit
Strategy & Ops
- Re-establishing stand-alone operating cadence after ~9+ months under pending acquisition
- Guidance on expense profile: expect cash-based operating expenses to increase no more than 10% in 2026 (commercial activities largely driving increases)
- Rev-rec / mix expectations by geography: in U.S. revenue requires installation/training/customer acceptance (vs faster recognition OUS when system ships); expectation that U.S. sold-vs-placed system mix may shift downward as OUS ramps slower
- International restart dynamic: tenders and distributor planning cycles slow immediate OUS ramp; potential near-term loss of some renewals/opportunities
Market Outlook
- FY2026 gross margin forecast: 46% to 49% (more system sales expected to improve mix within that range)
- Recurring revenue trajectory: recurring revenue annualizes to >$50M as of Q4; expectation that 200 installed systems continue producing
- Operational timing: 'next several quarters of 2026' gradual return to historical performance; OUS growth expected to 'begin to return' over time, with clearer ramp 'into 2027 / first, second quarter of 2027' especially for Southeast Asia
- Average procedures: US ALLY units expected ~600 procedures/year on a going-forward average, with new-customer ramp taking ~1-2 quarters
Risks & Headwinds
- Distributor conservatism/OUS uncertainty delayed activity for ~9 months; conservatism tied to uncertainty about post-termination tender timelines and planning for life without LENSAR
- Potential near-term churn/lost renewals in some tender-based opportunities where distributors waited to re-engage
- Short-term international system sales constrained: only 1 ALLY sale outside U.S. in Q4 2025 vs 10 in Q4 2024; FY2025 OUS system sales declined to 20 from 23 (and were heavily front-loaded in Q1 2025 pre-acquisition announcement: 8 systems, 40% of FY system sales)
- Competitive dynamic in the U.S.: competitors 'lack the system' and may use procedure-driven competitive pricing, potentially affecting U.S. sales mix and ramp pace
- Margin headwinds: inflationary raw material/production costs and tariffs assessed in 2025 without passing tariff costs to customers
Sentiment: MIXED
Note: This summary was synthesized by AI from the LNSR Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.